Richard Pops, chief executive  of Alkermes at their Dublin offices. Photograph: Aidan Crawley

Revenue at Irish drug group Alkermes jumped almost 24 per cent in the first three months of the year, to $161.2 million, ahead of analyst expectations(...)

Joe Papa CEO and president of Perrigo, which has rejected a $29 billion bid from rival Mylan. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Dublin-based Perrigo has rejected a $29 billion bid from generics group Mylan. The company said its board unanimously rejected the $205 per share offe(...)

AIB is a significant provider of seed capital funding in Ireland. It has committed €90 million to six funds, which have a combined size of €343 million

AIB has committed €15 million to a dedicated life-sciences venture-capital fund managed by Dublin-based Fountain Healthcare Partners. AIB is investing(...)

A generic form of the drug Plavix sits on crates at a Mylan Pharmaceuticals distribution centre in North Carolina.  Mylan has offered to acquire Perrigo for about $29 billion in what would be the latest mega-merger among drug makers if it is completed. Photograph: Travis Dove/The New York Times

Drugmaker Mylan offered to buy rival Perrigo for $28.9 billion in a deal that would create a powerhouse for generic medicine. Mylan, which makes abo(...)

Malin has decided to target the funding needs of privately held early-stage life sciences business.

The Elan gene pool delivers once again. It would be wrong to suggest that the business – since subsumed into generics and over-the-counter specialist (...)

Dr Ivan Coulter, founder and chief executive of Sigmoid, said the company had raised €25 million since it was founded in 2003. Photograph: Alan Betson

Sigmoid Pharma, a Dublin-based drug developer, has raised €5 million in new investment from Canadian company Pendopharm. The Irish firm, which is base(...)

Civitas is developing an inhaled form of the drug levadopa that is currently used by Parkinson’s patients in tablet form.

Irish private equity group Fountain Healthcare is one of the big winners following the sale of a company that has developed a experimental therapy fo(...)

Mathew Martoma, a former portfolio manager with SAC Capital Advisor Photographer: Peter Foley/Bloomberg

Mathew Martoma has been sentenced to nine years in prison for carrying out one of the biggest insider trading schemes on record in 2008 when he was w(...)

M&A activity in Ireland is at its strongest since 2008 with 42 deals announced during the first half of the year, according to new figures compile(...)

Steven Cohen: a judge ruled yesterday that the entire case against him and SAC can go forward. Photograph: Scott Eells/Bloomberg

A US federal judge has rejected billionaire investor Steven A Cohen’s bid to dismiss lawsuits by shareholders of pharma firms Elan and Wyeth who clai(...)